For this position, the recruiting organisation is the Medicines Evaluation Board (MEB) in Utrecht, the Netherlands. The selected candidate will be employed by the MEB and embedded in the POLARIS consortium. Academic interaction will take place with the Amsterdam Leukodystrophy Center at Amsterdam UMC and with the Amsterdam UMC platform Medicijn voor de Maatschappij, a partner of RARE-NL.

Keywords

#Regulatory science · #Patient access · #Orphan drugs · #Access and reimbursement

Medicines Evaluation Board (MEB), Utrecht

  • The Netherlands

The Medicines Evaluation Board is the Dutch regulatory authority responsible for assessing the efficacy, risks and quality of medicines. Within POLARIS, MEB contributes expertise in regulatory science, orphan-drug development, public-policy perspectives and access pathways for innovative therapies. This position provides a unique opportunity to connect scientific innovation in rare diseases with the regulatory, organisational and societal conditions required for responsible and sustainable patient access.

PhD project description

This doctoral project focuses on regulatory pathways, sustainable access and reimbursement for leukodystrophy therapies.

The candidate will investigate how innovative treatments for rare neurological diseases can move through regulatory frameworks and reach patients in a timely, equitable and sustainable way. The project will address key questions related to regulatory pathways, market access, health-system readiness and reimbursement models for emerging therapies, including advanced therapy medicinal products.

The research is situated at the interface of regulatory science, rare disease policy, health economics and translational medicine. It is expected to include the analysis of regulatory, organisational and scientific factors that influence the success of academic orphan-drug development; the evaluation of manufacturing and quality requirements for small-scale and n-of-few advanced therapies; the study of public-private partnership needs for registration and sustainable access; and the assessment of how clinical outcomes and patient-reported outcomes inform regulatory and health-technology-assessment decision-making.

The project will also explore cross-border access and reimbursement pathways in Europe and socially responsible models for sustainable access to innovative therapies. Planned secondments and network-wide training activities within POLARIS will provide broader interdisciplinary insight into therapy development, stakeholder perspectives and implementation challenges. In the POLARIS Description of Action, planned secondments are listed at Amsterdam UMC and Eberhard Karls University of Tübingen.

The academic embedding will be linked to the broader POLARIS doctoral training programme, with the host institution providing the regulatory and access perspective that complements the scientific and translational work of the network.

Eligibility criteria

Important, strict eligibility criteria according to MARIE SKLODOWSKA CURIE programs apply to applicants:

  1. You must not already hold a doctoral degree.
  2. At the time of the application deadline, you must have a Master’s degree and must not have resided or carried out your main activity (work, studies, etc.) in the Netherlands for more than 12 months in the three years prior to the contract start date.
  3. You will participate in the network-wide training programme of POLARIS, which includes (international) training activities and planned secondments with POLARIS partner organizations throughout the EU.

Requirements and candidate profile

We are looking for a motivated candidate with a Master’s degree in pharmaceutical sciences, health sciences, public health, biomedical sciences, regulatory science, health economics, law or a related field. You have a strong interest in innovative therapies for rare diseases and in the regulatory, societal and economic conditions required to make such therapies accessible to patients.

Experience or demonstrated interest in regulatory affairs, market access, health technology assessment, reimbursement systems, policy analysis or qualitative and mixed-methods research would be considered an advantage. An interest in orphan-drug policy, advanced therapy medicinal products, cross-border access issues and the interaction between scientific evidence, regulation and reimbursement would be particularly relevant for this position.

You are interested in working across disciplinary boundaries and in engaging with scientific, regulatory, clinical and societal perspectives. You work accurately and independently, have strong analytical and communication skills, and are able to collaborate effectively in an interdisciplinary and international environment.

Terms of employment

  • A contract for 12 months, with the intention to extend for a total of 3 years;
  • Salary, mobility allowance and benefits according to the applicable MSCA Doctoral Network and host-organisation rules;
  • Embedding in the international POLARIS doctoral training network;
  • Access to network-wide training activities, secondments and transferable-skills development;
  • A challenging and translational research project at the interface of in vivo neuroscience, rare disease biology and preclinical therapy development;
  • A collaborative and entrepreneurial working environment;
  • An open and supportive team culture with opportunities for scientific and professional development.

Recruitment procedure and application

Applications for the doctoral positions have now closed. The selection process is currently ongoing, and applications are being reviewed by the recruiting institutions.

POLARIS is now moving into the next phase of its doctoral programme, which will bring together a new cohort of researchers working across disciplines and sectors to advance translational research in leukodystrophies.